Seattle, WA, United States of America

Christopher Gabel

USPTO Granted Patents = 3 

 

Average Co-Inventor Count = 5.0

ph-index = 3

Forward Citations = 30(Granted Patents)


Company Filing History:


Years Active: 2011-2014

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Christopher Gabel: Innovator in Polypeptide Research

Introduction

Christopher Gabel is a notable inventor based in Seattle, WA. He has made significant contributions to the field of biotechnology, particularly in the development of polypeptides. With a total of 3 patents to his name, Gabel's work has the potential to impact various therapeutic applications.

Latest Patents

Gabel's latest patents include innovative compositions and methods related to IL-1Rrp2 requiring proteins. His first patent, IL-1F8 polypeptides, provides compositions and methods that enhance the understanding of these proteins. The second patent, IL-1F5 polypeptides, similarly focuses on compositions and methods related to IL-1Rrp2 requiring proteins. These inventions showcase his dedication to advancing medical science.

Career Highlights

Christopher Gabel is currently employed at Amgen Inc., a leading biotechnology company. His role at Amgen allows him to collaborate with other experts in the field and contribute to groundbreaking research. His work has been instrumental in developing new therapeutic strategies.

Collaborations

Gabel has worked alongside talented colleagues, including John Ernest Sims and Blair R Renshaw. These collaborations have fostered a creative environment that encourages innovation and the sharing of ideas.

Conclusion

Christopher Gabel is a prominent inventor whose work in polypeptide research is paving the way for future advancements in biotechnology. His contributions are significant and reflect his commitment to improving health outcomes through innovative solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…